Aspirin Resistance in Patients with Acute Ischemic Stroke

Overview

Journal J Neurol

Specialty Neurology

Date 2011 Apr 22

PMID 21509427

Citations 9

Authors

Serkan Ozben

Beste Ozben

Azra Meryem Tanrikulu

Feriha Ozer

Tomris Ozben

Affiliations

Soon will be listed here.

Abstract

Aspirin is used in ischemic stroke therapy. However, some patients are not responsive to the antithrombotic action of aspirin. The aim of this study was to assess the prevalence of aspirin resistance in stroke patients and its association with mortality. One-hundred and six patients (mean age 64.9 ± 14.6 years, 53 male) with acute ischemic stroke were consecutively recruited. All subjects were taking aspirin regularly. Aspirin responsiveness was determined by Ultegra Rapid Platelet Function Assay-ASA (VerifyNow Aspirin). Aspirin resistance was defined as aspirin reaction unit (ARU) ≥ 550. Aspirin resistance was detected in 35 patients. There were not any significant differences in age, gender and comorbidities between aspirin-resistant and aspirin-sensitive patients. The mean National Institute of Health Stroke Scale (NIHSS) scores of the aspirin-resistant and aspirin-sensitive patients were 15 ± 3 and 12 ± 5, respectively (p = 0.006). Twenty-seven patients had a history of prior ischemic stroke and eight of them had aspirin resistance. Eleven patients died in-hospital and a total of 43 patients died during 2 years. Both the in-hospital and 2-year mortality rates were significantly higher in patients with aspirin resistance (20 vs. 5.6%, p = 0.038 and 60.0 vs. 31.0%, p = 0.004, respectively). Regression analysis revealed aspirin resistance [odds ratio (OR) 3.097, 95% confidence interval (CI) 1.070-8.959, p = 0.037] as an independent predictor of 2-year mortality, as well as age (OR 1.051, 95% CI 1.003-1.102, p = 0.038) and NIHSS scores (OR 1.208, 95% CI 1.016-1.437, p = 0.033). Aspirin resistance is not uncommon in patients with acute ischemic stroke and is associated with short and long term mortality in these patients.

Citing Articles

Impact of pharmacogenetics on aspirin resistance: a systematic review.

da Silva G, Lopes B, Moser V, Ecker Ferreira L Arq Neuropsiquiatr. 2023; 81(1):62-73.

PMID: 36918009 PMC: 10014202. DOI: 10.1055/s-0042-1758445.

Effectiveness of Platelet Function Analysis-Guided Aspirin and/or Clopidogrel Therapy in Preventing Secondary Stroke: A Systematic Review and Meta-Analysis.

Yan A, Naunton M, Peterson G, Fernandez-Cadenas I, Mortazavi R J Clin Med. 2020; 9(12).

PMID: 33271959 PMC: 7760730. DOI: 10.3390/jcm9123907.

High On-Treatment Platelet Reactivity Affects the Extent of Ischemic Lesions in Stroke Patients Due to Large-Vessel Disease.

Wisniewski A, Sikora J, Slawinska A, Filipska K, Karczmarska-Wodzka A, Serafin Z J Clin Med. 2020; 9(1).

PMID: 31963511 PMC: 7019536. DOI: 10.3390/jcm9010251.

Antiplatelet therapy following ischaemic stroke - Continue or change pre-existing therapy?.

Mazlan-Kepli W, MacIsaac R, Walters M, Bath P, Dawson J Eur Stroke J. 2019; 2(1):31-36.

PMID: 31008300 PMC: 6453173. DOI: 10.1177/2396987316678728.

Biochemical aspirin resistance is associated with increased stroke severity and infarct volumes in ischemic stroke patients.

Cheng X, Xie N, Xu H, Chen C, Lian Y Oncotarget. 2017; 8(44):77086-77095.

PMID: 29100372 PMC: 5652766. DOI: 10.18632/oncotarget.20356.

References

Grotemeyer K, Scharafinski H, Husstedt I . Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res. 1993; 71(5):397-403. DOI: 10.1016/0049-3848(93)90164-j. View

Bhatt D, Fox K, Hacke W, Berger P, Black H, Boden W . Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354(16):1706-17. DOI: 10.1056/NEJMoa060989. View

. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988; 2(8607):349-60. View

Bennett D, Yan B, MacGregor L, Eccleston D, Davis S . A pilot study of resistance to aspirin in stroke patients. J Clin Neurosci. 2008; 15(11):1204-9. DOI: 10.1016/j.jocn.2008.01.006. View

Bogousslavsky J, van Melle G, Regli F . The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke. 1988; 19(9):1083-92. DOI: 10.1161/01.str.19.9.1083. View

Mueller M, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D . Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997; 78(3):1003-7. View

Kahraman G, Sahin T, Kilic T, Baytugan N, Agacdiken A, Ural E . The frequency of aspirin resistance and its risk factors in patients with metabolic syndrome. Int J Cardiol. 2007; 115(3):391-6. DOI: 10.1016/j.ijcard.2006.10.025. View

. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329):71-86. PMC: 64503. DOI: 10.1136/bmj.324.7329.71. View

Eikelboom J, Emery J, Hankey G . The use of platelet function assays may help to determine appropriate antiplatelet treatment options in a patient with recurrent stroke on baby aspirin: against. Stroke. 2010; 41(10):2398-9. DOI: 10.1161/STROKEAHA.110.593582. View

10.

Harrison P, Segal H, Silver L, Syed A, Cuthbertson F, Rothwell P . Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets. 2008; 19(2):119-24. DOI: 10.1080/09537100701771736. View

11.

Gorog D, Sweeny J, Fuster V . Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact?. Nat Rev Cardiol. 2009; 6(5):365-73. DOI: 10.1038/nrcardio.2009.13. View

12.

Krasopoulos G, Brister S, Beattie W, Buchanan M . Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008; 336(7637):195-8. PMC: 2213873. DOI: 10.1136/bmj.39430.529549.BE. View

13.

Jeon S, Song H, Kim B, Kim H, Kang D, Kim J . Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. Eur Neurol. 2010; 64(1):51-7. DOI: 10.1159/000315147. View

14.

Hankey G, Eikelboom J . Aspirin resistance. BMJ. 2004; 328(7438):477-9. PMC: 351832. DOI: 10.1136/bmj.328.7438.477. View

15.

Fateh-Moghadam S, Plockinger U, Cabeza N, Htun P, Reuter T, Ersel S . Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol. 2005; 42(2):99-103. DOI: 10.1007/s00592-005-0186-y. View

16.

Geisler T, Gawaz M . [Resistance to antiplatelet substances--a real clinical problem]. Herz. 2008; 33(4):260-8. DOI: 10.1007/s00059-008-3128-y. View

17.

Zimmermann N, Wenk A, Kim U, Kienzle P, Weber A, Gams E . Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation. 2003; 108(5):542-7. DOI: 10.1161/01.CIR.0000081770.51929.5A. View

18.

Zytkiewicz M, Gielwanowska L, Wojtasinska E, Psuja P, Zawilska K . Resistance to acetylsalicylic acid in patients after ischemic stroke. Pol Arch Med Wewn. 2009; 118(12):727-33. View

19.

Yip H, Liou C, Chang H, Lan M, Liu J, Chen M . Link between platelet activity and outcomes after an ischemic stroke. Cerebrovasc Dis. 2005; 20(2):120-8. DOI: 10.1159/000086802. View

20.

Chen W, Lee P, Ng W, Tse H, Lau C . Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol. 2004; 43(6):1122-6. DOI: 10.1016/j.jacc.2003.12.034. View